Company / Cash & Equivalents
Amylyx Pharmaceuticals, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$226.7M
FY2025
5-year range
$50.2M / $226.7M
FY2021-FY2025
Trend
+192.9%
vs FY2024
Sector context
#75 of 207
Health Care
What the data says
At $227M, Amylyx Pharmaceuticals, Inc.'s cash & equivalents ranks #75 of 207 in the Health Care sector. Improved from $170M to $227M over the past 2 years.
Based on SEC 10-K filings.
$227M in FY2025 with a 3-year CAGR of +53.6%.
Improved from $170M to $227M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +53.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#75 of 207 in Health CareTop 36% of 207This company $226.7M Sector average $669.5M
▼
-66.1% below sector average
Key checks
Key Insights
- 3-year CAGR of +53.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 192.9% year-over-year.
- Ranks #75 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $226.7M | +192.9% |
| FY2024 | $77.4M | -54.5% |
| FY2023 | $170.2M | +172.2% |
| FY2022 | $62.5M | +24.6% |
| FY2021 | $50.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026